ROFLUMILAST – A new drug developed to treat Seborrheic Dermatitis

US FDA has recently approved ROFLUMILAST foam for treating moderate to severe seborrheic dermatitis.

It is developed by Arcutis Biotherapeutics.

The drug is useful for treating a skin condition called seborrheic dermatitis in individuals nine years of age and older.

Roflumilast becomes the first topical drug for treating seborrheic dermatitis.

Seborrheic dermatitis, a common, chronic and recurrent inflammatory skin disease.

It is a common skin condition that mainly affects your scalp. It causes scaly patches, inflamed skin and stubborn dandruff.

It usually affects oily areas of the body, such as the face, sides of the nose, eyebrows, ears, eyelids and chest.